IA
EWTX icon

IFP Advisors’s Edgewise Therapeutics EWTX Stock Holding History

IFP Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$163 Hold
4
– – ﹤0.01% 4893
2026
Q1 		$126 Hold
4
– – ﹤0.01% 4704
2025
Q4 		$99 Hold
4
– – ﹤0.01% 4593
2025
Q3 		$65 Buy
+4
New +$57 ﹤0.01% 4612
2025
Q2 		– Hold
0
– – – 3585
2025
Q1 		– Hold
0
– – – 3967
2024
Q4 		– Hold
0
– – – 4109

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IFP Advisors's EWTX Position: Q2 2026 in Review

IFP Advisors held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 4 shares worth $163. The position accounts for ﹤0.01% of the portfolio, ranked #4893.

IFP Advisors first reported a position in EWTX in Q3 2025 and has held it in 4 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • IFP Advisors held 4 shares of Edgewise Therapeutics worth $163 as of Q2 2026.
  • IFP Advisors left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4893 holding.
  • IFP Advisors first reported a position in Edgewise Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.